We provide you with 20 years of free, institutional-grade data for CGON stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CGON. Explore the full financial landscape of CGON stock.
Total insider purchase within 3 month on this page: $24,814,453
Total insider selling within 3 month on this page: -$1,986,531
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Liu Brian Guan-Chyun | Open Market Purchase | 371,085 | $66.87 | 2026-06-29 | |
| POST LEONARD E | Sale | -5,000 | $70 | $350,000 | 2026-06-25 |
| POST LEONARD E | Derivatives Exercise | 5,000 | 2026-06-25 | ||
| POST LEONARD E | Sale | -5,000 | $65 | $325,000 | 2026-06-23 |
| POST LEONARD E | Derivatives Exercise | 5,000 | 2026-06-23 | ||
| Mulay James | Sale | -1,964 | $60.12 | $118,076 | 2026-06-16 |
| Mulay James | Derivatives Exercise | 1,964 | 2026-06-16 | ||
| POST LEONARD E | Sale | -1,000 | $54.5 | $54,500 | 2026-06-05 |
| POST LEONARD E | Derivatives Exercise | 1,000 | 2026-06-05 | ||
| Mulay James | Sale | -15,600 | $73.01 | $1,138,956 | 2026-04-20 |
| Mulay James | Derivatives Exercise | 15,600 | 2026-04-20 | ||
| Mulay James | Sale | -1,964 | $63.5 | $124,714 | 2026-03-17 |
| Mulay James | Derivatives Exercise | 1,964 | 2026-03-17 | ||
| Kuan Arthur | Sale | -1,847 | $60.15 | $111,097 | 2026-03-13 |
| Kuan Arthur | Derivatives Exercise | 64,612 | 2026-03-13 | ||
| Kuan Arthur | Sale | -2,871 | $61.61 | $176,882 | 2026-03-06 |
| Kuan Arthur | Derivatives Exercise | 102,871 | 2026-03-06 | ||
| Mulay James | Sale | -11,145 | $44.16 | $492,163 | 2026-01-13 |
| Mulay James | Derivatives Exercise | 11,145 | 2026-01-13 | ||
| POST LEONARD E | Sale | -1,000 | $41.43 | $41,430 | 2025-11-18 |
| POST LEONARD E | Derivatives Exercise | 1,000 | 2025-11-18 | ||
| POST LEONARD E | Sale | -1,000 | $43.25 | $43,250 | 2025-10-15 |
| POST LEONARD E | Derivatives Exercise | 1,000 | 2025-10-15 | ||
| Mulay James | Sale | -5,903 | $43.99 | $259,673 | 2025-10-10 |
| Mulay James | Derivatives Exercise | 5,903 | 2025-10-10 |
The information provided in this report about CGON stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
CG Oncology Inc.(NASDAQ:CGON) 
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer.
Share this website to your friends